Avelumab: all 201 studies that test it
Page 2 of 3. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic AdenocarcinomaActive, not recruitingNCT05102721Phase 1/2
- Study of Avelumab in Combination With Lenvatinib for Children With Primary CNS TumorsTerminatedNCT05081180Phase 1
- Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast CancerActive, not recruitingNCT04841148Phase 2
- Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell CarcinomaActive, not recruitingNCT04792073Phase 2
- Cryoablation With Pembrolizumab Or Avelumab In Urothelial CarcinomaCompletedNCT04701918Phase 2
- Avelumab Plus Intermittent Axitinib in Previously Untreated Patients With Metastatic Renal Cell CarcinomaStatus unknownNCT04698213Phase 2
- GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 TherapyCompletedNCT04601402Phase 1
- Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid TumorsStatus unknownNCT04571632Phase 2
- NPC - AXEL Study : Axitinib-AvelumabCompletedNCT04562441Phase 2
- Avelumab Plus Cetuximab in Pre-treated RAS Wild Type Metastatic Colorectal CancerCompletedNCT04561336Phase 2
- AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer PatientsCompletedNCT04513951Phase 2
- Immune Checkpoint Inhibitor In High Risk Oral Premalignant LesionsStatus unknownNCT04504552Phase 2
- Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingNCT04387084Phase 1
- PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast CancerActive, not recruitingNCT04360941Phase 1
- Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell CarcinomaActive, not recruitingNCT04291885Phase 2
- Study of DCC-3014 in Combination With Avelumab in Patients With Advanced or Metastatic SarcomasCompletedNCT04242238Phase 1
- Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal TherapyActive, not recruitingNCT04071236Phase 1/2
- Intratumoral Microdosing of TAK-981 in Head and Neck CancerCompletedNCT04065555Early Phase 1
- Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial CarcinomaActive, not recruitingNCT04004442Phase 1
- Avelumab + Paclitaxel/ Ramucirumab (RAP) as Second Line Treatment in Gastro-esophageal AdenocarcinomaStatus unknownNCT03966118Phase 2
- TALAVE: Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast CancerActive, not recruitingNCT03964532Phase 1/2
- Bladder PREserVation by RadioTherapy and Immunotherapy in BCG Unresponsive Non-muscle Invasive Bladder CancerStatus unknownNCT03950362Phase 2
- KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder CancerTerminatedNCT03915405Phase 1
- AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse GliomaCompletedNCT03893903Phase 1
- Avelumab as Single Agent in Metastatic or Locally Advanced Urothelial Cancer in Patients Unfit for Cisplatin. The ARIES StudyCompletedNCT03891238Phase 2
- A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid TumorsTerminatedNCT03861403Phase 1
- Immunotherapy In Locally Advanced Rectal CancerCompletedNCT03854799Phase 2
- Targeting the Tumor Microenvironment in R/M SCCHNStatus unknownNCT03844763Phase 1/2
- Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon CancerTerminatedNCT03827044Phase 3
- Avelumab With Axitinib in Persistent or Recurrent Cervical Cancer After Platinum-based ChemotherapyCompletedNCT03826589Not applicable
- Avelumab Program Rollover StudyActive, not recruitingNCT03815643Phase 3
- Epigenetic Modulation of the immunE Response in GastrointEstinal Cancers (EMERGE)Status unknownNCT03812796Phase 2
- The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT03800953Phase 2
- Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile CarcinomaStatus unknownNCT03774901Phase 2
- VXM01 Plus Avelumab Combination Study in Progressive GlioblastomaStatus unknownNCT03750071Phase 1/2
- Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial CancerActive, not recruitingNCT03744793Phase 2
- Avelumab With Radiotherapy in Patients With Leptomeningeal DiseaseCompletedNCT03719768Phase 1
- Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)WithdrawnNCT03699384Phase 1/2
- QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.WithdrawnNCT03647423Phase 1/2
- Avelumab in the Frontline Treatment of Advanced Classical Hodgkin Lymphoma - a Window StudyActive, not recruitingNCT03617666Phase 2
- Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable CancerStatus unknownNCT03608046Phase 2
- A Combination of Avelumab and Taxane (AVETAX) for Urothelial CancerCompletedNCT03575013Phase 1
- QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung CancerWithdrawnNCT03574649Phase 2
- Immunotherapy in Combination With Chemotherapy in Small-cell Lung CancerCompletedNCT03568097Phase 2
- QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) VaccineWithdrawnNCT03563170Phase 1/2
- QUILT-3.088: NANT Pancreatic Cancer VaccineWithdrawnNCT03563144Phase 2
- QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) VaccineWithdrawnNCT03554109Phase 2
- Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has SpreadActive, not recruitingNCT03547973Phase 2
- Avelumab in Combination With Gemcitabine in Advanced Leiomyosarcoma as a Second-line TreatmentStatus unknownNCT03536780Phase 2
- PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)CompletedNCT03514719Phase 1
- Paclitaxel-Avelumab for AngiosarcomaStatus unknownNCT03512834Phase 2
- Carboplatin, Paclitaxel With or Without Avelumab in Advanced or Recurrent Endometrial CancerStatus unknownNCT03503786Phase 2
- Avelumab, Cetuximab, and Palbociclib in Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT03498378Phase 1
- K-Basket, Avelumab, Biomarker-driven, Advanced Solid TumorStatus unknownNCT03491345Phase 2
- Avelumab/Gemcitabine in Sarcomatoid RCCTerminatedNCT03483883Phase 1
- A Trial of PEGPH20 in Combination With Avelumab in Chemotherapy Resistant Pancreatic CancerTerminatedNCT03481920Early Phase 1
- Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]Status unknownNCT03439501Phase 2
- A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With AvelumabCompletedNCT03409458Phase 1/2
- Avelumab in Refractory Testicular Germ Cell Cancer.CompletedNCT03403777Phase 2
- Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive ChemotherapyTerminatedNCT03395873Phase 1
- A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based ChemotherapyActive, not recruitingNCT03391479Phase 2
- Avelumab Plus Carboplatin-gemcitabine in Urothelial CarcinomaCompletedNCT03390595Phase 2
- Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib TreatmentCompletedNCT03389126Phase 2
- Avelumab With Valproic Acid in Virus-associated CancerCompletedNCT03357757Phase 2
- Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After ChemotherapyCompletedNCT03352934Phase 2
- Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCCStatus unknownNCT03341845Phase 2
- Avelumab With Laser Interstitial Therapy for Recurrent GlioblastomaCompletedNCT03341806Phase 1
- First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder CarcinomaTerminatedNCT03324282Phase 2
- Avelumab With Chemoradiation in Locally Advanced Rectal CancerCompletedNCT03299660Phase 2
- Clinical Trial on the Combination of Avelumab and Axitinib for the Treatment of Patients With Recurrent GlioblastomaCompletedNCT03291314Phase 2
- Avelumab in G3 NECCompletedNCT03278405Phase 1/2
- Avelumab in G2-3 NETCompletedNCT03278379Phase 2
- Adjuvant Avelumab in Merkel Cell CancerActive, not recruitingNCT03271372Phase 3
- A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based TherapyCompletedNCT03270176Phase 1
- Neoadjuvant Avelumab and Hypofractionated Proton Radiation Therapy Followed by Surgery for Recurrent Radiation-refractory MeningiomaTerminatedNCT03267836Phase 1
- A Study to Evaluate eFT508 Alone and in Combination With Avelumab in Subjects With MSS Colorectal CancerCompletedNCT03258398Phase 2
- Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP StudyActive, not recruitingNCT03244176Early Phase 1
- QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint InhibitorsActive, not recruitingNCT03228667Phase 2
- Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)CompletedNCT03200587Phase 1
- QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) TherapyWithdrawnNCT03197584Phase 1/2
- QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03197571Phase 1/2
- Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic CancerCompletedNCT03186326Phase 2
- QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based ChemotherapyWithdrawnNCT03175666Phase 1/2
- Avelumab and Cetuximab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer - The Phase II AVETUX-CRC Trial.CompletedNCT03174405Phase 2
- QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHLWithdrawnNCT03169790Phase 1/2
- QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCWithdrawnNCT03169777Phase 1/2
- QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03169764Phase 1/2
- QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 InhibitorsWithdrawnNCT03169738Phase 1/2
- QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 TherapyWithdrawnNCT03167177Phase 1/2
- QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 TherapyWithdrawnNCT03167164Phase 1/2
- UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC PatientsCompletedNCT03158883Early Phase 1
- Avelumab Plus Autologous Dendritic Cell Vaccine in Pre-treated Metastatic Colorectal Cancer PatientsCompletedNCT03152565Phase 1/2
- Avelumab for MSI-H or POLE Mutated Metastatic Colorectal CancerStatus unknownNCT03150706Phase 2
- Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular SubtypesCompletedNCT03147404Phase 2
- A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based ChemotherapyActive, not recruitingNCT03076554Phase 2
- Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell CarcinomaWithdrawnNCT03035630Phase 2
- Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH)Active, not recruitingNCT02999087Phase 3
- Bioimmunoradiotherapy (Cetuximab/RT/Avelumab)CompletedNCT02938273Phase 1
- Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody AvelumabCompletedNCT02926196Phase 3
- Therapies in Combination or Sequentially With Tyrosine Kinase Inhibitors (TKIs) in Chronic Phase Chronic Myelogenous Leukemia Patients in CCR (ACTIW)Active, not recruitingNCT02767063Phase 1/2